ECSP992896A - FORMULATIONS FOR THE PROTECTION OF CONJUGATES FROM PEG- INTERFERON ALFA - Google Patents
FORMULATIONS FOR THE PROTECTION OF CONJUGATES FROM PEG- INTERFERON ALFAInfo
- Publication number
- ECSP992896A ECSP992896A ECSP992896A ECSP992896A EC SP992896 A ECSP992896 A EC SP992896A EC SP992896 A ECSP992896 A EC SP992896A EC SP992896 A ECSP992896 A EC SP992896A
- Authority
- EC
- Ecuador
- Prior art keywords
- peg
- formulations
- interferon alpha
- present
- conjugates
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 102000006992 Interferon-alpha Human genes 0.000 title abstract 2
- 108010047761 Interferon-alpha Proteins 0.000 title abstract 2
- 229950000038 interferon alfa Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 4
- 229940079322 interferon Drugs 0.000 abstract 4
- 230000015556 catabolic process Effects 0.000 abstract 3
- 238000006731 degradation reaction Methods 0.000 abstract 3
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 238000012792 lyophilization process Methods 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona formulaciones que previenen la pérdida y el daño de conjugados de PEG-interferon alfa durante y después de la liofilización. Las formulaciones de la presente invención protegen los conjugados de PEG-interferon alfa contra la pérdida y degradación durante el proceso de liofilización, asi como también contra la degradación durante el posterior almacenamiento. Las formulaciones de la presente invención son adecuadas para la protección de conjugados de PEG-interferón alfa contra varios tipos de degradación incluyendo, pero no limitándose, a la pérdida de actividad biológica y cambios en el grado y/o naturaleza de la conjugación. Un conjugado de PEG-interferón alfa preferido capaz de ser protegido en las formulaciones de la presente invención es un conjugado de interferón alfa -2b-polietilenglicol (12.000).The present invention provides formulations that prevent the loss and damage of PEG-interferon alpha conjugates during and after lyophilization. The formulations of the present invention protect the PEG-interferon alpha conjugates against loss and degradation during the lyophilization process, as well as against degradation during subsequent storage. The formulations of the present invention are suitable for the protection of PEG-interferon alpha conjugates against various types of degradation including, but not limited to, loss of biological activity and changes in the degree and / or nature of conjugation. A preferred PEG-interferon alpha conjugate capable of being protected in the formulations of the present invention is an interferon alpha -2b-polyethylene glycol conjugate (12,000).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP992896 ECSP992896A (en) | 1999-03-24 | 1999-03-24 | FORMULATIONS FOR THE PROTECTION OF CONJUGATES FROM PEG- INTERFERON ALFA |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP992896 ECSP992896A (en) | 1999-03-24 | 1999-03-24 | FORMULATIONS FOR THE PROTECTION OF CONJUGATES FROM PEG- INTERFERON ALFA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP992896A true ECSP992896A (en) | 1999-06-01 |
Family
ID=42043884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP992896 ECSP992896A (en) | 1999-03-24 | 1999-03-24 | FORMULATIONS FOR THE PROTECTION OF CONJUGATES FROM PEG- INTERFERON ALFA |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP992896A (en) |
-
1999
- 1999-03-24 EC ECSP992896 patent/ECSP992896A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5080738A1 (en) | FORMULATIONS FOR THE PROTECTION OF CONJUGATES OF PEGINTER- FERON ALFA | |
| NO20023315D0 (en) | G-CSF conjugates | |
| EA200300738A1 (en) | PROTECTION, RESTORATION AND STRENGTHENING OF ERYTHROPOYETHRACTIVE CELLS, TISSUES AND ORGANS | |
| ES2067256T3 (en) | BIOLOGICALLY ACTIVE PEPTIDES CONTAINING D-2-ALKYL TRYPTOPHANE. | |
| ES2167377T3 (en) | DERIVATIVES OF PIRIDINA PHARMACOLOGICALLY ACTIVE AND PROCEDURES FOR THE PREPARATION OF THE SAME. | |
| DK1021204T3 (en) | Bioadhesive compositions and methods for topical administration of active agents | |
| DK0388220T3 (en) | Preparations for sustained release of chlorhexidine | |
| DK1246639T3 (en) | GLP-2 formulations | |
| LU90987I2 (en) | Copaxone and its pharmaceutically acceptable derivatives | |
| ES8701196A1 (en) | A PROCEDURE FOR THE PREPARATION OF DIPEPTIDES DERIVED FROM THIAZOLINE. | |
| ES2163444T3 (en) | COMPOSITIONS AND METHODS FOR THE ORAL ADMINISTRATION OF PHARMACOS. | |
| ATE244015T1 (en) | FORMULATIONS FOR FACTOR IX | |
| EA200500120A1 (en) | RECOMBINANT TISSUE PROTECTIVE CYTOKINES AND Coding NUCLEIC ACIDS FOR PROTECTION, RESTORATION AND ENHANCEMENT OF SENSITIVE CELLS, TISSUES AND ORGANS | |
| BG91270A (en) | ANTIVIRAL AND ANTIBACTERIAL AGENT AND METHOD OF ITS USE | |
| PA8504401A1 (en) | PHARMACEUTICALLY ACTIVE COMPOUNDS | |
| BR0210056A (en) | compositions and methods for treating hyperplasia | |
| MY129356A (en) | Electrospun pharmaceutical compositions | |
| FI940779A0 (en) | New Cetrorelix Lyophilisate Preparation Procedure | |
| ES2192839T3 (en) | TIMOSINA BETA 4 OXIDADA. | |
| ATE279910T1 (en) | SURFACTANT FOR EXTERNAL SKIN PREPARATIONS AND EXTERNAL SKIN PREPARATIONS CONTAINING SAME | |
| BR0215303A (en) | Water-based pharmaceutical formulations of water-soluble propofol prodrugs | |
| CO5540370A2 (en) | COMPRESSED UNDERSTANDING CETIRIZINE AND PSEUDOEFREDINA | |
| DK0801571T3 (en) | Soluble 2'-chloro-2'-deoxyadenosion formulations | |
| BR0208860A (en) | Use of a cationic dextran derivative, method for protecting an individual against dose-limiting organ damage, and method for protecting an individual against renal damage | |
| ES2152269T3 (en) | INHIBITORS OF RIBONUCLEOTIDO-REDUCTASA DE HERPESVIRUS. |